- Home
- FUSB vs GUTS Comparison
FUSB vs GUTS Comparison
Compare FUSB & GUTS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FUSB
- GUTS
- Stock Information
- Founded
- FUSB 1952
- GUTS 2010
- Country
- FUSB United States
- GUTS United States
- Employees
- FUSB N/A
- GUTS N/A
- Industry
- FUSB Major Banks
- GUTS
- Sector
- FUSB Finance
- GUTS
- Exchange
- FUSB Nasdaq
- GUTS NYSE
- Market Cap
- FUSB 72.6M
- GUTS 58.8M
- IPO Year
- FUSB N/A
- GUTS 2024
- Fundamental
- Price
- FUSB $13.00
- GUTS $1.52
- Analyst Decision
- FUSB
- GUTS Buy
- Analyst Count
- FUSB 0
- GUTS 1
- Target Price
- FUSB N/A
- GUTS $10.00
- AVG Volume (30 Days)
- FUSB 2.2K
- GUTS 785.4K
- Earning Date
- FUSB 07-23-2025
- GUTS 08-13-2025
- Dividend Yield
- FUSB 2.15%
- GUTS N/A
- EPS Growth
- FUSB N/A
- GUTS N/A
- EPS
- FUSB 1.28
- GUTS N/A
- Revenue
- FUSB $38,449,000.00
- GUTS $60,000.00
- Revenue This Year
- FUSB N/A
- GUTS N/A
- Revenue Next Year
- FUSB N/A
- GUTS N/A
- P/E Ratio
- FUSB $10.16
- GUTS N/A
- Revenue Growth
- FUSB N/A
- GUTS N/A
- 52 Week Low
- FUSB $9.17
- GUTS $0.87
- 52 Week High
- FUSB $14.30
- GUTS $4.92
- Technical
- Relative Strength Index (RSI)
- FUSB 53.63
- GUTS 41.63
- Support Level
- FUSB $12.53
- GUTS $1.47
- Resistance Level
- FUSB $13.23
- GUTS $1.68
- Average True Range (ATR)
- FUSB 0.26
- GUTS 0.14
- MACD
- FUSB 0.01
- GUTS -0.03
- Stochastic Oscillator
- FUSB 65.14
- GUTS 9.80
About FUSB First US Bancshares Inc.
First US Bancshares Inc is a bank holding company. The Bank conducts general commercial banking business and offers banking services such as demand, savings, individual retirement account and time deposits, personal and commercial loans, safe deposit box services, and remote deposit capture. The Bank provides a range of commercial banking services to small and medium-sized businesses, property managers, business executives, professionals, and other individuals.
About GUTS FRACTYL HEALTH INC
Fractyl Health Inc is a metabolic therapeutics company focused on pioneering new approaches to the treatment of metabolic diseases, including type 2 diabetes and obesity. The company focuses on transforming metabolic disease treatment from chronic symptomatic management to durable disease modifying therapies that target the organ level root causes of T2D and obesity.